Company: GHRS
Filing Date: 2025-07-29
Form Type: 20-F/A
Source: 0001140361-25-027850
Chunk: 41

Company: GH Research PLC
Filing Date: 2025-07-29
Form: 20-F/A
Chunk 41
---
 we could be sued and held liable for injury caused to individuals exposed to or taking our product candidates or operating our medical devices; and |

| • | our reputation may suffer. |

In addition, patients who participate in our trials may take antidepressants or other medications to treat depression and/or mood disorders, or other medications that may interact with our product candidates, and participation in our clinical trials currently requires patients to suspend most of such existing medications or treatments for the duration of the trial. If a patient chooses to resume his or her existing medications, there is no guarantee such medications will produce the same therapeutic effect, if any, as may have been experienced prior to suspending such medication. Further, the impact of cycling off and/or back on to existing medications could have undesirable side effects or lead to severe mental health trauma. Any such negative reactions of a patient participating in one of our clinical trials may decrease the willingness of patients to participate in our trials, affect the timing or outcome of our clinical trials, product candidate development and approval process, or create negative public perception around our product candidates, which in turn may significantly impact our ability to successfully commercialize our product candidates. Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidates, could negatively impact the perception of our other product candidates, could substantially increase the costs of commercializing our product candidates, if approved, and significantly impact our ability to successfully commercialize our product candidates and generate revenues. If we encounter difficulties enrolling patients in our future clinical trials, our clinical development activities could be delayed or otherwise adversely affected. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. 20 Table of Contents Patient enrollment is affected by many factors, including:

| • | the patient eligibility criteria defined in the protocol; |

| • | the size of the patient population required for analysis of the trial’s primary endpoints; |

| • | in the case of clinical trials focused on rare disease, the small size of the patient population and the potential of a patient being undiagnosed or misdiagnosed; |

| • | the proximity of patients to trial sites; |

| • | the design of the trial; |

| • | our ability to recruit clinical trial investigators with the appropriate competencies and experience; |

| • | competing clinical trials and clinicians’ and patients’ perceptions